What Is Semax?
Semax is a synthetic heptapeptide and analogue of the ACTH(4–10) fragment, with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro.
Chemically, Semax contains the ACTH-derived Met-Glu-His-Phe sequence followed by a Pro-Gly-Pro tripeptide, giving the compound its seven-amino-acid structure.
Research Overview Table
Chemical and Molecular Characteristics
Certificates:
Mechanism of Action Under Investigation
Semax shows specific and reversible binding to membrane associated sites, with calcium ions required for the interaction. Dipeptidylaminopeptidases have also been identified as enzymes involved in its degradation, producing the peptide fragments HFPGP and PGP.
Published research has associated Semax with changes in BDNF and TrkB expression and signaling. A recent study also reported the μ-opioid receptor as a Semax target and linked it with USP18 regulation and FTO deubiquitination. The relationship between these molecular findings and a single mechanism remains unresolved.
Scientific Research Context
Semax has been examined in connection with neurotrophin expression, peptide binding and changes in cellular gene activity. Research has included biochemical work, cultured glial cells, and investigations of gene expression in brain tissue. Studies have measured factors such as BDNF and NGF, along with their related transcripts and receptors. Other work has examined the peptide’s interaction with copper ions. The literature therefore covers several biochemical and neurobiological questions, with evidence derived primarily from in vitro research and preclinical animal models.
Semax Biology and Biological Pathways
Primary Biological Function
Semax is a synthetic peptide, so an endogenous physiological function has not been established. Research has instead examined biological processes associated with neurotrophins. BDNF and NGF are involved in neuronal survival, differentiation, and maintenance. Semax-related studies have therefore focused on changes in these neurotrophin systems.
Relevant Metabolic or Signalling Pathways
The main biological pathways examined include the BDNF/TrkB system and NGF-related signaling. Research has measured BDNF protein, TrkB phosphorylation, and expression of Bdnf, Ngf, and neurotrophin receptor genes. Calcium regulation has also been examined in relation to neuronal cellular activity.
Tissue-Specific Biology
Semax-related neurotrophin responses are not uniform across neural tissues. The hippocampus, frontal cortex, retina, brainstem, basal forebrain, and cerebellum have shown distinct patterns of BDNF or NGF expression. In particular, increased BDNF was reported in the basal forebrain but not the cerebellum, while hippocampal, cortical, and retinal tissues showed differing expression patterns.
Experimental Biomarkers
Semax studies have measured BDNF, NGF, TrkB, TrkA, and TrkC at the gene or protein level. BDNF protein and TrkB phosphorylation have also been assessed. Other Semax research has measured CREB, JNK, MMP-9, and c-Fos protein expression.
Laboratory Investigation Methods
Published Semax research has used real-time PCR, immunoenzymatic analysis, radioligand binding and HPLC with UV detection. These methods have been applied to measure gene expression, quantify BDNF protein, characterize peptide-binding sites, and analyze Semax degradation products.
Experimental Models Used in Published Research
Semax has been examined in cultured neural cells, isolated brain membranes, brain-slice preparations, and intact rodent models. These systems differ in biological complexity. Their limitations mainly involve loss of normal cellular interactions, tissue organization, neural connections, or species-specific biology.
Primary Neuronal and Glial Cell Cultures
Primary neuronal and glial cultures provide isolated neural cells outside their normal tissue environment. Their main limitation is the loss of intact neural architecture, multicellular interactions and systemic physiological influences.
PC12 Cell Model
PC12 is a rat pheochromocytoma-derived cell line. Its tumor origin and non-neuronal lineage limit its representation of normal neural cells.
Brain Membrane Preparations
Brain plasma membrane preparations retain membrane associated components but lack intact cellular organization. Their limitation is the absence of intracellular structures and interactions between complete neural cells.
Brain-Slice Preparations
Hippocampal and cerebellar slices are ex vivo neural-tissue models. Their limitation is that sectioning removes normal vascular supply and connections with neural regions outside the prepared slice.
Rodent Models
Rodent models, including rats and mice are established experimental systems in Semax research. Their limitation is species-specific biology, so findings from these animals cannot be assumed to reproduce human physiology.
Semax Published Research
Neurotrophin Gene Expression
Semax-related changes in BDNF, NGF, NT-3, TrkA, TrkB, and TrkC transcripts have been measured. Reported expression patterns differed by brain region and time point, including changes in hippocampal, cortical, and other neural tissues. The evidence is predominantly preclinical.
BDNF and TrkB Signaling
Semax-related changes in the BDNF/TrkB system have been investigated at several levels. Published measurements included BDNF protein, BDNF mRNA, TrkB mRNA, and TrkB tyrosine phosphorylation. The reported work therefore examined both BDNF expression and TrkB receptor activation.
VEGF Family Gene Expression
The Semax study investigated Vegf-a, Vegf-b, Vegf-c, Vegf-d, Plgf, Vegfr-1, Vegfr-2, and Vegfr-3 gene expression by measuring their mRNA levels.
Neurotrophin Expression During Cerebral Ischemia
The study investigated Bdnf, Ngf, Nt-3, TrkA, TrkB, and TrkC transcription following cerebral ischemia. Semax-associated changes in these neurotrophin and receptor genes were measured at different post-ischemic time points.
Immune-Related Gene Expression
The investigation covered immune response genes, including immunoglobulin, chemokine, cytokine, antigen-presentation and interferon-related genes. Specific transcripts examined included Il1b, Il6, Ccl3, Socs3, Hspb1, and Fos.
Neurotransmitter-Related Gene Expression
RNA sequencing investigated genes associated with neurotransmission and changes in their transcript levels following Semax exposure. The analysis included genes such as Chrm1, Chrm4, Drd1, Drd2, Gabra5, Gria3, Grm3, Grm5, Htr6, Neurod6, Gpr6 and Gpr88.
Brain Protein Expression
The study investigated CREB, JNK, MMP-9, and c-Fos protein expression, including the phosphorylated forms pCREB and pJNK. It also measured Mmp9 and Fos mRNA expression.
Semax Binding
Researchers examined specificity, reversibility, calcium dependence, binding kinetics, Kd, and Bmax for Semax binding to brain membrane preparations.
Limitations of Current Research
Evidence Is Predominantly Preclinical
Much of the Semax literature comes from experimental cellular and animal research. These studies examine molecular and biological responses under controlled conditions, but their findings do not establish how those responses translate to human biology.
Human Clinical Evidence
Human clinical studies of Semax are available, but they vary in design and reporting. Published trials include small patient groups, comparative studies and an open-label clinical trial. These differences, together with limited methodological detail in some reports, make the clinical evidence difficult to compare consistently.
Species Differences
Rodent research forms an important part of the Semax literature. Differences between rodents and humans in brain organization, receptor biology, metabolism and other physiological characteristics create uncertainty when experimental findings are extended across species.
Study Design Limitations
The clinical literature includes different study designs, control arrangements, sample sizes and assessment methods. For example, one clinical investigation enrolled 30 patients and compared them with 80 controls, while another used an open-label design. Such differences make direct comparison difficult.
Independent Replication
Several Semax investigations originate from the same research networks and institutions. Repeated findings across related research groups do not provide the same evidence as independent replication using separate investigators, populations and protocols. Broader replication would help determine how consistently the reported observations can be reproduced.
Long-Term Evidence
Long-term Semax exposure has not been well characterized in controlled clinical research. Published clinical studies generally used short treatment courses, such as 5–10 days or two 10-day courses. Consequently, evidence remains limited regarding effects associated with prolonged exposure or repeated treatment over longer periods.
Analytical Documentation
HPLC separates Semax from related substances and provides chromatographic purity data. It can also support batch-to-batch analytical comparison.
LC-MS provides mass-based information that helps confirm peptide identity and detect related molecular species. Published Semax analysis has used mass spectrometric methods for peptide identification.
NMR can provide structural information when suitable sample quantity and experimental conditions allow its use. It is not necessarily required for routine peptide testing.
A Certificate of Analysis (CoA) documents analytical results for a specific batch, including the tested material, analytical methods, and measured values.
Analytical documentation helps establish material identity, purity, and traceability for laboratory research. It verifies product identity and quality, not biological performance.
Storage and Laboratory Handling
Store Semax under the conditions listed in the product documentation. The provided Certificate of Analysis specifies 2–8°C. Qualified laboratory personnel should handle the material using standard laboratory practices. Keep the material in its original container and use clean equipment to help prevent contamination.
Maintain the batch information and analytical records for laboratory traceability. Follow established procedures for receiving, storage, handling, and disposal.
Why Researchers Choose Direct SARMs?
Direct SARMs is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.
Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.
Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs, we aim to make the research supply process simple, clear, and reliable.
Frequently asked questions
Why choose us?
Direct SARMs is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.
Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.
Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs, we aim to make the research supply process simple, clear, and reliable.